Latest Industry Insights

Learn from James Hallam, vice president of the Research, Development and Advanced Testing Business segment at Waters Corporation, about how technological advancements in mass spectrometry are powering new discoveries in omics research.

In bioanalysis, AI could alleviate preclinical and clinical bioanalytical data processing and analysis. Here, Mary Belfast from Teva Branded Pharmaceuticals, discusses some of the latest guidelines on AI implementation and validation in bioanalysis.

Technology Networks joined Tarun Anumol for a discussion about the major challenges facing PFAS testing at this year’s ASMS conference.

Technology Networks joined Agilent Technologies for a discussion about new advances in gas chromatography at this year’s ASMS conference.

Technology Networks joined Agilent Technologies for a discussion about the company’s latest product launches at this year’s ASMS conference.

We sat down with Dr. John Puglia, senior director of research and development at Thermo Fisher, to learn more about their new biobased films and other sustainability initiatives.

We sat down with Professor Peter Van Eenoo, director of the Doping Control Laboratory (DoCoLab), part of the University of Ghent, Belgium, to discuss the intricacies of anti-doping testing and the challenges faced in catching sporting cheats.

In this interview, Dr. Becky Upton discusses the key findings of a recent survey conducted by the Pistoia Alliance regarding the use of AI in life sciences and the main hurdles preventing wider adoption of AI in pharma.

In this article, Michelle Fraser and Amanda Haupthow discuss how engineered nucleases in combination with next-generation base editing platforms are paving the way for the development of novel treatments for genetic disorders and diseases.

In this interview, Technology Networks spoke with Dr. Roy Maute, co-founder and CEO of Pheast Therapeutics, to learn about macrophage checkpoint therapies and the potential they hold for cancer treatment.